p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma

American Journal of Surgical Pathology

Volumn 22, Issue 12, 1998, Pages 1463-1473

  Zheng, Wenxin ^a,e   Khurana, Renu ^a   Farahmand, Shirin ^b   Wang, Yulai ^c   Zhang, Zuo Feng ^d   Felix, Juan C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Carcinoma in situ; Endometrial carcinoma; P53 immunohistochemistry; Precursor lesions; Uterine surface carcinoma

Indexed keywords

PROTEIN P53;

ARTICLE; CARCINOGENESIS; CLINICAL FEATURE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PAPILLARY CARCINOMA; UTERUS CARCINOMA;

AGED; ANTIBODIES, MONOCLONAL; CARCINOMA IN SITU; CYSTADENOCARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PRECANCEROUS CONDITIONS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031769404     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199812000-00003     Document Type: Article

References (27)

1. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Human Pathol 1995;26:1260-7.
2. Banks L, Matlashewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529-34.
3. Begg CB. Biases in the assessment of diagnostic tests. Stat Med 1987;6:411-23.
4. Bohkman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
5. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98: 81-7.
6. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study of 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992;47:298-305.
7. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985;56:1452-5.
8. Fanning J, Evans MC, Peters AJ, Samuel M, Marmon ER, Bates JS. Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. Gynecol Oncol 1989;32:288-91.
9. Finlay CA, Hinds PW, Tan TW, Eliyahu D, Oren EM, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
10. Gurpide E. Endometrial cancer: biochemical and clinical correlates. J Natl Cancer Inst 1991;83:405-16.
11. Hanley JA, McNeil JB. The meaning and use of the area under the receiver operating characteristic curve. Radiology 1982;143:29-36.
12. Hendrickson M, Martinez A, Ross J, Kempson R, Eifel P. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
13. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52: 1622-7.
14. Kohler MF, Nishii H, Humphrey PA, et al. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasia. Am J Obstet Gynecol 1993;169:690-4.
15. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, ed. Blaustein's Pathology of The Female Genital Tract. New York: Springer-Verlag; 1994:439-86.
16. Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 1981;105:615-8.
17. Okamoto A, Sameshima Y, Yamada Y, Teshima S, Terashima Y, Terada M, Yokota J. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 1991;51:5632-6.
18. Ponder B. Gene losses in human tumors. Nature 1988;335:400-2.
19. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16:600-10.
20. Sherman M, Bur ME, Kurman RJ. p53 in endometrial cancers and its putative precursors: evidence for diverse pathways of tumori-genesis. Hum Pathol 1995;26:1268-74.
21. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990;3:120-8.
22. Silverberg SG, Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease. In: Rosai J, ed. Atlas of Tumor Pathology. Third series, Fasicle 3. Washington, DC: Armed Forces Institute of Pathology; 1992:191-204.
23. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995;19:417-32.
24. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
25. Walker AN, Mills SE. Serous papillary carcinoma of the endometrium: a clinicopathological study of 11 cases. Diagn Gynecol Obstet 1982;4:261-7.
26. Zheng W, Cao P, Zheng M, Kramer EE, Godwin T. p53 and bcl-2 expression in endometrial adenocarcinoma. Comparison of serous and endometrioid subtypes (see comments). Gynecol Oncol 1996; 61:167-74.
27. Zheng W, Sung CJ, Cao P, Cai R, Godwin TA, Kramer EE, Lauchlan SC. The early occurrence and prognostic significance of p53 in primary carcinoma of the fallopian tube. Gynecol Oncol 1997;64: 38-48.